Peer-reviewed veterinary case report
Feline injection-site sarcoma treatment options and outcomes
By Zabielska-Koczywąs, Katarzyna et al.·Published in Acta veterinaria Scandinavica·2017·Department of Small Animal Diseases with Clinic·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Current knowledge on feline injection-site sarcoma treatment.
- Species:
- cat
Plain-English summary
A cat with a malignant skin tumor, known as feline injection-site sarcoma (FISS), can be challenging to treat. The best approach combines surgery with radiation therapy, which helps ensure clean surgical margins and lowers the chance of the tumor returning. In some cases, chemotherapy may be used to help manage the disease or support the main treatments. New treatments, like immunotherapy and advanced medications, are also being explored to improve outcomes for cats with this condition. Overall, early and aggressive treatment can lead to better survival rates for affected cats.
People also search for: cat injection-site sarcoma treatment · feline cancer surgery options · cat skin tumor chemotherapy · feline immunotherapy for cancer
Abstract
Feline injection-site sarcomas (FISS) are malignant skin tumours of mesenchymal origin, the treatment of which is a challenge for veterinary surgeons. The role of surgery, radiotherapy and chemotherapy in FISS treatment has been studied, and a correlation between "clean" surgical margins and disease-free survival has been shown. In addition, clean surgical margins are one of the most important factors for achieving a low recurrence rate. The most effective method of FISS treatment includes combining radical surgery with pre- or postoperative radiotherapy. Chemotherapy may be used as a palliative method of treatment or may be considered an adjunctive therapy for surgery and radiotherapy. In cats with FISS without metastasis, the use of immunostimulant treatment with Oncept IL-2, intended as a complementary immunotherapy in association with surgery and brachytherapy, may also be considered to reduce the risk of relapse and increase the time to relapse. Additionally, this review focuses on recent advances in FISS treatment, including the use of novel compounds, such as doxorubicin conjugated to glutathione-stabilized gold nanoparticles, liposomal doxorubicin or tyrosine kinase inhibitors.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28716129/